Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United States - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36819162/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: The primary objective was to provide real-world experience with zanubrutinib in patients with WM. Secondary objectives included limited assessment of safety and efficacy.
A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?
Source : https://www.sciencedirect.com/science/article/pii/S1936523323000220?via=ihub
PD-1 may probably be the more attractive ICI target rather than PD-L1 and CTLA-4 in NHL cases. * In T-NHLs, MF and ENKTL had the best responses to PD-1 inhibitors....
Conclusions: While MF, ENKTL, RT, and PMBCL showed promising responses to ICI monotherapy, neither FL nor DLBCL had satisfactory responses; further necessitating novel strategies such as the application of ICIs in combination with other treatment strategies. Notably, among different combinations, BTK inhibitors showed an obvious improvement...
Pirtobrutinib preclinical characterization: a highly selective, non-covalent (reversible) BTK inhibitor
Research Article | Eliana B Gomez, Kevin Ebata, Hetal S Randeria, Mary S Rosendahl, Ernst Peder Cedervall, Tony H Morales, Lauren M Hanson, Nicholas E Brown, Xueqian Gong, Jennifer Rachelle...
Conclusions: Pirtobrutinib is efficacious in B-cell models in vitro and in vivo, including patient derived CLL cells.
-
Leukemia and Lymphoma Connect2yrKey Points • Source: Blood • Conclusions/Relevance: “Collectively, these findings suggest pirtobrutinib represents a novel BTK inhibitor with improved selectivity and unique pharmacologic, biophysical and structural attributes with the potential to treat B-cell driven Show More
Use of CAM among cancer patients - BMC Complementary Medicine and Therapies
Source : https://bmccomplementmedtherapies.biomedcentral.com/articles/10.1186/s12906-023-03876-2
Background The use of complementary and alternative medicine (CAM) by patients is widespread. However, there is a lack of knowledge regarding the extent and details of patient CAM use in...
Conclusions: The use of CAM is common among patients with cancer in the region of Gävleborg, and previous studies show a similar use in Sweden in general. Based on the widespread use of CAM and patient interest in discussing CAM use with healthcare professionals, greater attention and focus should be placed on creating a basis for this...
Sulfamate Acetamides as Self-Immolative Electrophiles for Covalent Ligand-Directed Release Chemistry - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36738297/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Electrophiles for covalent inhibitors that are suitable for in vivo administration are rare. While acrylamides are prevalent in FDA-approved covalent drugs, chloroacetamides are considered too reactive for such purposes. We report sulfamate-based electrophiles that maintain chloroacetamide-like geometry with tunable reactivity. In...